NICE announces start of review of nusinersen Managed Access Agreement
NICE has today (29 October 2020) announced that it has begun the process to review data collected as part of the Managed Access Agreement (MAA) for nusinersen (also called Spinraza and made by Biogen) for treating the rare genetic disorder spinal muscular atrophy (SMA).
-
Test people with womb cancer for inherited genetic condition, NICE says in new guidance
Research led by Professor Emma Crosbie, with Professor Gareth Evans and Dr Neil Ryan from The University of Manchester and Manchester University NHS Foundation Trust, showed the benefits of different testing strategies for Lynch syndrome in womb cancer cases in increasing diagnosis of the condition.
-
NICE gears up to support World Evidence-based Healthcare Day
Inaugural World Evidence-based Healthcare (EBHC) Day takes place on Tuesday 20 October 2020
-
NICE draft guidance recommends siponimod for treating secondary progressive multiple sclerosis
NICE has today (15 October 2020) issued draft guidance which now recommends siponimod (also called Mayzent and made by Novartis) for treating secondary progressive multiple sclerosis (MS).
